BioMark Diagnostics, Inc. is a canadian-based company, which engages in the development and commercialization of cancer diagnostic solutions to detect, monitor, and assess treatment for cancer. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2014-11-03. The firm's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. The company is also engaged in developing accessible diagnostic solutions to address unmet medical needs in oncology. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a liquid biopsy metabolic panel assay, which is instrumental for early-stage diagnosis of lung cancer.
